- Home
- ARAY vs LRMR Comparison
ARAY vs LRMR Comparison
Compare ARAY & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARAY
- LRMR
- Stock Information
- Founded
- ARAY 1990
- LRMR N/A
- Country
- ARAY United States
- LRMR United States
- Employees
- ARAY N/A
- LRMR N/A
- Industry
- ARAY Medical/Dental Instruments
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- ARAY Health Care
- LRMR Health Care
- Exchange
- ARAY Nasdaq
- LRMR Nasdaq
- Market Cap
- ARAY 229.3M
- LRMR 183.8M
- IPO Year
- ARAY 2007
- LRMR N/A
- Fundamental
- Price
- ARAY $1.78
- LRMR $2.00
- Analyst Decision
- ARAY
- LRMR Strong Buy
- Analyst Count
- ARAY 0
- LRMR 10
- Target Price
- ARAY N/A
- LRMR $19.60
- AVG Volume (30 Days)
- ARAY 382.4K
- LRMR 906.5K
- Earning Date
- ARAY 04-30-2025
- LRMR 05-08-2025
- Dividend Yield
- ARAY N/A
- LRMR N/A
- EPS Growth
- ARAY N/A
- LRMR N/A
- EPS
- ARAY N/A
- LRMR N/A
- Revenue
- ARAY $453,140,000.00
- LRMR N/A
- Revenue This Year
- ARAY $6.97
- LRMR N/A
- Revenue Next Year
- ARAY $5.02
- LRMR N/A
- P/E Ratio
- ARAY N/A
- LRMR N/A
- Revenue Growth
- ARAY 1.26
- LRMR N/A
- 52 Week Low
- ARAY $1.40
- LRMR $1.96
- 52 Week High
- ARAY $2.95
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- ARAY 38.43
- LRMR 29.98
- Support Level
- ARAY $1.75
- LRMR $2.19
- Resistance Level
- ARAY $1.89
- LRMR $2.44
- Average True Range (ATR)
- ARAY 0.07
- LRMR 0.18
- MACD
- ARAY 0.01
- LRMR -0.01
- Stochastic Oscillator
- ARAY 25.00
- LRMR 4.81
About ARAY Accuray Incorporated
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.